Pink Sheet is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By


Cinnamon drugs for diabetes

This article was originally published in The Tan Sheet

Executive Summary

PhytoMedical Technologies plans to fast-track development of a new drug class of cinnamon-derived polyphenolic compounds that could be used to treat type-2 diabetes, the firm announces Dec. 6. The compounds "possess unique antioxidant and insulin enhancing qualities" distinct from existing classes of diabetes drugs, the Princeton, N.J.-based firm states. According to results from a study of patients with type-2 diabetes, the compounds reduced levels of blood sugar by an average of 18% to 29%, triglycerides by 23% to 30%, LDL cholesterol by 7% to 27% and overall cholesterol by 12% to 26% without side effects, the company says. PhytoMedical plans to end its initial research and development work at the beginning of February and begin drug development in order to quickly pursue its investigational new drug (IND) application with FDA, according to company President & CEO Greg Wujek. The firm plans to begin Phase I human trials as soon as FDA approves the IND, according to the company...

You may also be interested in...

EU’s SCCS Finds Endocrine-Disrupting Evidence Inconclusive In UV Filter Reassessments

While endocrine-disrupting evidence was inconclusive, the Scientific Committee on Consumer Safety recommends more conservative limits on use of homosalate, octocrylene and benzophenone-3 in cosmetic products compared with current requirements under the European Cosmetics Product Regulation.

US FDA Urges COVID-19 Transmission Risk Mitigation In Cell And Gene Therapy Manufacturing

The risk of inadvertently growing SARS-CoV-2 virus in cell and gene therapies and possibly infecting patients and workers should be assessed and mitigated, the agency advises.

COVID-19: US Acted To Beat Other Countries To Next 1.25M Doses Of Regeneron Cocktail

Move was meant to preempt others’ efforts to secure the next six months of Regeneron’s COVID-19 antibody therapeutic.





Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts